Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Clinical evidence

STRIDE

66 evidence topics · 12 sources

Objective
Location and study date
Countries of trial sites in the ClinicalTrials.gov record
Study design
Eligibility criteria
Exclusion criteria on prior treatment washout and lack of response to biologic therapies in the protocol

“5. Has used topical medications/treatments that could affect psoriasis evaluation within 2 weeks of the first administration of study drug” (opens the source at this quote in a new tab)

“6. Has received phototherapy or any systemic medications/treatments that could affect psoriasis evaluation within 4 weeks of Study Day 1” (opens the source at this quote in a new tab)

“7. Has received any therapeutic agent targeted to: IL-12or IL-23 within 6 months, IL-17 within 4 months, or any TNFα inhibitor(s) within 2 months of first administration of study drug” (opens the source at this quote in a new tab)

“8. Is currently receiving or has received any systemic immunosuppressants or immunomodulatory drugs (e.g., methotrexate, cyclosporine) within 4 weeks of the first administration of study drug or 5 half-lives whichever is longer” (opens the source at this quote in a new tab)

“9. Has received agents that modulate B cells (e.g., rituximab, ocrelizumab) within 6 months of first administration of study drug” (opens the source at this quote in a new tab)

“10. Has received agents that modulate T cells (e.g., abatacept, alemtuzumab) within 3 months of first administration of study drug” (opens the source at this quote in a new tab)

“11. Has received JAK inhibitors (e.g., baricitinib, tofacitinib) or TYK2 inhibitors within 4 weeks of first administration of study drug” (opens the source at this quote in a new tab)

“12. History of lack of clinical response to any therapeutic agent targeted to IL-12, IL-17 or IL-23 (e.g., ustekinumab, risankizumab, secukinumab, ixekizumab) at approved doses after at least 3 months of treatment” (opens the source at this quote in a new tab)

“13. History of lack of clinical response, in the Investigator’s opinion, to 2 or more biologic therapies at approved doses after at least 3 months of treatment” (opens the source at this quote in a new tab)

“14. Has received any investigational agent, within 30 days or 5 half-lives (whichever is longer) of any study drug or is currently enrolled in an investigational study” (opens the source at this quote in a new tab)

Exclusion criteria on QTcF, cardiovascular disease, infections, and laboratory values in the protocol

“16. Patients with QTcF >450 msec (males) or >470 msec (females) at screening” (opens the source at this quote in a new tab)

“17. Unstable cardiovascular disease, defined as a recent clinical deterioration (e.g., unstable angina, rapid atrial fibrillation) or a cardiac hospitalization within the last 3 months” (opens the source at this quote in a new tab)

“18. Active herpes viral infection, including herpes simplex 1 and 2 and herpes zoster identified on examination and/or medical history within 2 months of administration of study drug” (opens the source at this quote in a new tab)

“19. Patients with hepatitis C virus (HCV), or hepatitis B virus (HBV) or human immunodeficiency virus (HIV) or active or inadequately treated latent tuberculosis (TB) infection at screening” (opens the source at this quote in a new tab)

“20. Has any of the following lab abnormalities:” (opens the source at this quote in a new tab)

“Absolute neutrophil count <1.5 X 10^9/L” (opens the source at this quote in a new tab)

“Hemoglobin <9 g/dL” (opens the source at this quote in a new tab)

“AST/ALT ≥2 x upper limit of normal (ULN)” (opens the source at this quote in a new tab)

“Albumin <3 g/dL” (opens the source at this quote in a new tab)

“Total bilirubin ≥2 x ULN (patients with a history of Gilbert’s syndrome are not eligible)” (opens the source at this quote in a new tab)

“Glomerular filtration rate <50 (Cockcroft and Gault method)” (opens the source at this quote in a new tab)

“22. History of serious bacterial, fungal, or viral infections that led to hospitalization and IV antibiotic treatment within 90 days prior to screening, or any recent serious infection requiring antibiotic treatment within 30 days of Study Day 1” (opens the source at this quote in a new tab)

Exclusion criteria on corticosteroid-requiring conditions, malignancy, live vaccines, surgery, and mental illness in the protocol

“21. History of any immune-mediated or inflammatory medical condition for which patient requires current systemic (oral, SC, IM or IV) corticosteroids” (opens the source at this quote in a new tab)

“23. Known current malignancy or current evaluation for a potential malignancy or history of malignancy within the past 5 years prior to screening, except for adequately treated basal cell skin carcinoma, carcinoma in situ of the cervix and breast ductal carcinoma in situ” (opens the source at this quote in a new tab)

“24. Live vaccines (e.g., varicella, measles, mumps, rubella, cold-attenuated intranasal influenza vaccine, and bacillus Calmette-Guérin) within 4 weeks of Study Day 1” (opens the source at this quote in a new tab)

“25. Patient has a known hypersensitivity to any component of the study drug” (opens the source at this quote in a new tab)

“26. Patient has planned surgery during the study period” (opens the source at this quote in a new tab)

“27. Any acute or chronic illness/condition or evidence of an unstable clinical condition that in the investigator’s judgement will substantially increase the risk to the patient if he or she participates in the study” (opens the source at this quote in a new tab)

“28. History of mental illness within the last 5 years, unless the patient fulfills one of the following conditions:” (opens the source at this quote in a new tab)

“Receiving a fixed regimen of psychiatric medications for at least 6 months before screening, displays no sign of acute mental illness and, in the opinion of the investigator, the patient is able and safe to participate in the study” (opens the source at this quote in a new tab)

“Has not required or been prescribed any psychiatric medication (including but not limited to antidepressants or anxiolytics) within 12 months before screening and, in the opinion of the investigator, the patient is able and safe to participate in the study” (opens the source at this quote in a new tab)

“29. Patient who, for any reason, is deemed by the investigator to be inappropriate for this study or is unable to comply with the study protocol” (opens the source at this quote in a new tab)

Treatment
Arms and tablet regimens in the ClinicalTrials.gov results
Study outcomes
Rationale for using PASI 75 response as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants per arm in the intent-to-treat, modified intent-to-treat, and safety analysis sets of the published article
Analysis set (table)PlaceboESK-001 10 mg QDESK-001 20 mg QDESK-001 20 mg BIDESK-001 40 mg QDESK-001 40 mg BID
Intent-to-treat (Table I)“(N = 38)”“(N = 36)”“(N = 36)”“(N = 40)”“(N = 39)”“(N = 39)”
Modified intent-to-treat (Table II)“(N = 38)”“(N = 36)”“(N = 36)”“(N = 39)”“(N = 39)”“(N = 39)”
Safety (Table III)“(N = 38)”“(N = 36)”“(N = 36)”“(N = 39)”“(N = 39)”“(N = 39)”
Analysis set (table)Pooled ESK-001 column header
Intent-to-treat (Table I)“ESK-001 pooled (N = 190)”
Safety (Table III)“ESK-001 pooled (N = 189)”
Description of analysis sets
Analysis populations, stratification factors, multiplicity, and treatment-emergent period in the statistical analysis plan

“Modified Intent-to-Treat (mITT) Population: All randomized subjects who received at least one dose of study drug, with analyses conducted according to the assigned treatment. This will be the analysis population used for the primary efficacy analysis at Week 12.” (opens the source at this quote in a new tab)

“Intent-to-treat (ITT) Population: All randomized subjects, regardless of whether they receive study drug, with analyses conducted according to the assigned treatment.” (opens the source at this quote in a new tab)

“Per-protocol (PP) Population: All subjects in the ITT population who have received at least one dose of study drug as assigned, have both baseline and at least one post-baseline PASI score, and have no important protocol deviations (IPD) which may affect key primary and secondary efficacy endpoints in the treatment period.” (opens the source at this quote in a new tab)

“Safety Analysis Population: All randomized subjects who receive at least one dose of study drug with analyses conducted by actual treatment received.” (opens the source at this quote in a new tab)

“PK Analysis Population: All randomized subjects who receive at least 1 dose of ESK-001 and have at least one non-missing PK concentration with analysis conducted by actual treatment received.” (opens the source at this quote in a new tab)

“Prior use of biologics or JAK inhibitors (yes/no)” (opens the source at this quote in a new tab)

“Geographic region (North America /rest of world (ROW))” (opens the source at this quote in a new tab)

“No adjustments for multiplicity control will be performed in this study.” (opens the source at this quote in a new tab)

“The treatment emergent period is defined as first dose through the end of study for subjects who complete the full treatment period of 12 weeks.” (opens the source at this quote in a new tab)

“If a subject discontinues study drug early, then the treatment emergent period will be first dose through four weeks after last dose.” (opens the source at this quote in a new tab)

“Since the EQ-5D-5L value sets used to calculate the index score are country-specific and there currently are none available for Czech Republic where some subjects are enrolled in this study, the value set for Poland will be used instead as the closest Eastern European country with available scoring instrument.” (opens the source at this quote in a new tab)

Analysis population for each outcome measure in the ClinicalTrials.gov results
Results
Participant disposition
Participant flow by arm with reasons for not completing in the ClinicalTrials.gov results
Participant flow, overall studyPlaceboESK-001 10 mg QDESK-001 20 mg QDESK-001 20 mg BIDESK-001 40 mg QDESK-001 40 mg BID
Started“38”“36”“36”“40”“39”“39”
Completed“33”“36”“30”“37”“33”“35”
Not completed“5”“0”“6”“3”“6”“4”
Reason: adverse event“0”“0”“2”“0”“1”“1”
Reason: discontinued prior to dosing due to the blood sample logistics“0”“0”“0”“1”“0”“0”
Reason: lost to follow-up“0”“0”“2”“1”“1”“0”
Reason: protocol violation“0”“0”“0”“0”“2”“0”
Reason: subject can't continue with week 16 visit“0”“0”“1”“0”“0”“0”
Reason: terminated from the study due to sponsor requirements“0”“0”“0”“1”“0”“0”
Reason: withdrawal by subject“5”“0”“1”“0”“2”“3”
Baseline characteristics
Demographic and baseline disease characteristics by arm in the intent-to-treat set
CharacteristicPlacebo, N = 38ESK-001 10 mg QD, N = 36ESK-001 20 mg QD, N = 36ESK-001 20 mg BID, N = 40ESK-001 40 mg QD, N = 39ESK-001 40 mg BID, N = 39ESK-001 pooled, N = 190
Mean age, years (SD)“49 (11.7)”“49 (12.7)”“44 (12.0)”“48 (12.5)”“50 (10.4)”“48 (14.2)”“48 (12.4)”
Male, n (%)“31 (82)”“24 (67)”“24 (67)”“23 (58)”“26 (67)”“26 (67)”“123 (65)”
Female, n (%)“7 (18)”“12 (33)”“12 (33)”“17 (43)”“13 (33)”“13 (33)”“67 (35)”
Race, American Indian or Alaska Native, n (%)“0 (0)”“0 (0)”“1 (3)”“0 (0)”“1 (3)”“0 (0)”“2 (1)”
Race, Asian, n (%)“4 (11)”“1 (3)”“2 (6)”“2 (5)”“2 (5)”“2 (5)”“9 (5)”
Race, Black or African American, n (%)“3 (8)”“4 (11)”“0 (0)”“1 (3)”“1 (3)”“1 (3)”“7 (4)”
Race, Native Hawaiian or Other Pacific Islander, n (%)“0 (0)”“1 (3)”“0 (0)”“2 (5)”“0 (0)”“0 (0)”“3 (2)”
Race, White, n (%)“27 (71)”“30 (83)”“31 (86)”“34 (85)”“33 (85)”“33 (85)”“161 (85)”
Race, other, n (%)“4 (11)”“0 (0)”“2 (6)”“1 (3)”“2 (5)”“1 (3)”“6 (3)”
Race, not reported, n (%)“0 (0)”“0 (0)”“0 (0)”“0 (0)”“0 (0)”“2 (5)”“2 (1)”
Ethnicity, Hispanic or Latino, n (%)“13 (34)”“7 (19)”“14 (39)”“7 (18)”“13 (33)”“11 (28)”“52 (27)”
Ethnicity, not Hispanic or Latino, n (%)“24 (63)”“29 (81)”“21 (58)”“33 (83)”“26 (67)”“28 (72)”“137 (72)”
Ethnicity, not reported, n (%)“1 (3)”“0 (0)”“1 (3)”“0 (0)”“0 (0)”“0 (0)”“1 (1)”
Mean weight, kg (SD)“94 (21.4)”“92 (21.3)”“103 (39.1)”“95 (24.7)”“88 (19.1)”“91 (20.9)”“94 (26.1)”
Mean BMI, kg/m2 (SD)“32 (6.8)”“31 (5.9)”“35 (12.1)”“32 (7.4)”“30 (6.4)”“32 (7.1)”“32 (8.1)”
Mean duration of psoriasis, years (SD)“20 (11.6)”“19 (13.4)”“17 (8.3)”“22 (12.2)”“17 (12.4)”“22 (15.5)”“19 (12.7)”
Prior treatment with biologics or JAK inhibitors, n (%)“13 (34)”“13 (36)”“14 (39)”“16 (40)”“13 (33)”“13 (33)”“69 (36)”
Mean PASI score (SD)“18 (4.5)”“17 (3.9)”“19 (6.6)”“18 (6.5)”“17 (6.5)”“17 (4.9)”“18 (5.8)”
sPGA score 3 (moderate), n (%)“22 (58)”“24 (67)”“17 (47)”“23 (58)”“25 (64)”“23 (59)”“112 (59)”
sPGA score 4 (marked), n (%)“15 (40)”“9 (25)”“17 (47)”“16 (40)”“14 (36)”“16 (41)”“72 (38)”
sPGA score 5 (severe), n (%)“1 (3)”“3 (8)”“2 (6)”“1 (3)”“0 (0)”“0 (0)”“6 (3)”
Mean BSA, % (SD)“23 (12.1)”“21 (12.2)”“20 (12.6)”“21 (15.0)”“20 (12.9)”“22 (15.1)”“21 (13.5)”
Mean DLQI score (SD)“10 (7.2)”“10 (5.4)”“9 (7.6)”“10 (7.2)”“10 (6.4)”“11 (6.8)”“10 (6.7)”
Age categories by arm in the ClinicalTrials.gov results
Age category, participantsPlacebo, n = 38ESK-001 10 mg QD, n = 36ESK-001 20 mg QD, n = 36ESK-001 20 mg BID, n = 40ESK-001 40 mg QD, n = 39ESK-001 40 mg BID, n = 39Total, n = 228
18 years or younger“0”“0”“0”“0”“0”“0”“0”
Between 18 and 65 years“35”“33”“33”“35”“37”“33”“206”
65 years or older“3”“3”“3”“5”“2”“6”“22”
Efficacy results
PASI 75, PASI 90, PASI 100, sPGA 0/1, sPGA 0, and BSA results at week 12 by dose in the modified intent-to-treat set
Week 12 end pointPlacebo, N = 38ESK-001 10 mg QD, N = 36ESK-001 20 mg QD, N = 36ESK-001 20 mg BID, N = 39ESK-001 40 mg QD, N = 39ESK-001 40 mg BID, N = 39
PASI-75, n (%)“0 (0)”“7 (19)”“12 (33)”“22 (56)”“22 (56)”“25 (64)”
PASI-75, P value vs placebo“-”“0.0025”“0.0001”“<0.0001”“<0.0001”“<0.0001”
PASI-75, difference vs placebo, % (95% CI)“-”“19 (−3, 41)”“33 (11, 54)”“56 (37, 73)”“56 (37, 73)”“64 (46, 79)”
PASI-90, n (%)“0 (0)”“0 (0)”“4 (11)”“10 (26)”“10 (26)”“15 (39)”
PASI-90, P value vs placebo“-”“-”“.0322”“.0007”“.0005”“<.0001”
PASI-90, difference vs placebo, % (95% CI)“-”“-”“11 (−12,34)”“26 (4, 46)”“26 (4, 46)”“39 (17, 58)”
PASI-100, n (%)“0 (0)”“0 (0)”“0 (0)”“4 (10)”“3 (8)”“6 (15)”
PASI-100, P value vs placebo“-”“-”“-”“.0396”“.0712”“.0127”
PASI-100, difference vs placebo, % (95% CI)“-”“-”“-”“10 (−12, 32)”“8 (−15, 30)”“15 (−7, 37)”
sPGA-0/1, n (%)“3 (8)”“6 (17)”“14 (39)”“19 (49)”“21 (54)”“23 (59)”
sPGA-0/1, P value vs placebo“-”“.1965”“.0012”“<.0001”“<.0001”“<.0001”
sPGA-0/1, difference vs placebo, % (95% CI)“-”“9 (−14, 32)”“31 (8, 51)”“41 (20, 60)”“46 (26, 65)”“51 (31, 69)”
sPGA-0, n (%)“0 (0)”“0 (0)”“0 (0)”“4 (10)”“4 (10)”“9 (23)”
sPGA-0, P value vs placebo“-”“-”“-”“.0396”“.0333”“.0017”
sPGA-0, difference vs placebo, % (95% CI)“-”“-”“-”“10 (−12, 32)”“10 (−12,32)”“23 (1, 44)”
Mean BSA change from baseline (SD)“−3 (6.8)”“−7 (7.8)”“−7 (8.1)”“−14 (12.9)”“−15 (14.2)”“−14 (12.1)”
Primary end point, dose-dependent response, and key secondary end points in the published article

“ESK-001 demonstrated both clinically meaningful and statistically significant dose-dependent improvements in psoriasis skin severity and quality of life” (opens the source at this quote in a new tab)

“A dose-dependent effect was observed across all end points, with maximal ESK-001 efficacy observed in the highest dose arm (40 mg BID).” (opens the source at this quote in a new tab)

“More patients achieved PASI-75 in each of the ESK-001 dose arms compared with placebo: 64% in the 40 mg BID dose arm vs 0% in the placebo group (P < .0001) at week 12, meeting the primary end point.” (opens the source at this quote in a new tab)

“Likewise, all key secondary end points were met in the 20 mg BID, 40 mg QD, and 40 mg BID dose arms.” (opens the source at this quote in a new tab)

“In patients receiving ESK-001 40 mg BID, 39% (P < .0001) and 15% (P = .0127) achieved PASI-90 and PASI-100, respectively (placebo, 0%).” (opens the source at this quote in a new tab)

“Furthermore, 59% (P < .0001) and 23% (P = .0017) achieved sPGA-0/1 and sPGA-0, respectively (placebo, 8% and 0%, respectively).” (opens the source at this quote in a new tab)

“Clinical responses to ESK-001 were robust and increased over time in all ESK-001 dose arms.” (opens the source at this quote in a new tab)

“In the 3 highest dose groups, clinically meaningful improvements in the primary and all secondary end points were achieved, including PASI, sPGA, DLQI, pruritus, and % body surface area involvement (P < .001).” (opens the source at this quote in a new tab)

PASI 75 response rates with 95% confidence intervals in the ClinicalTrials.gov results
Week 12 outcomePlacebo, n = 38ESK-001 10 mg QD, n = 36ESK-001 20 mg QD, n = 36ESK-001 20 mg BID, n = 39ESK-001 40 mg QD, n = 39ESK-001 40 mg BID, n = 39
PASI-75, percentage (95% CI)“0 (0.0 to 9.3)”“19.4 (8.2 to 36.0)”“33.3 (18.6 to 51.0)”“56.4 (36.6 to 72.2)”“56.4 (39.6 to 72.2)”“64.1 (47.2 to 78.8)”
Health-related quality of life and patient-reported outcomes
DLQI 0/1, DLQI 4-point decrease, and pruritus NRS results at week 12 by dose in the modified intent-to-treat set
Week 12 patient-reported outcomePlacebo, N = 38ESK-001 10 mg QD, N = 36ESK-001 20 mg QD, N = 36ESK-001 20 mg BID, N = 39ESK-001 40 mg QD, N = 39ESK-001 40 mg BID, N = 39
DLQI-0/1, n (%)“7 (18)”“10 (28)”“12 (33)”“20 (51)”“19 (48)”“25 (64)”
DLQI-0/1, P value vs placebo“-”“.2807”“.1159”“.0016”“.0045”“<.0001”
DLQI-0/1, difference vs placebo, % (95% CI)“-”“9 (−10, 29)”“15 (−5, 35)”“33 (13, 53)”“30 (10, 50)”“46 (26, 65)”
DLQI 4-point decrease, n (%)“7 (19)”“18 (51)”“18 (51)”“25 (64)”“26 (70)”“24 (65)”
DLQI 4-point decrease, P value vs placebo“-”“.0032”“.0032”“.0001”“<.0001”“<.0001”
DLQI 4-point decrease, difference vs placebo, % (95% CI)“-”“33 (12, 53)”“33 (12, 53)”“45 (26, 65)”“51 (32, 71)”“46 (26, 66)”
Mean change from baseline in average pruritus NRS (SD)“−1 (3)”“−2 (3)”“−3 (3)”“−4 (3)”“−4 (3)”“−5 (3)”
Mean change from baseline in worst pruritus NRS (SD)“−1 (3)”“−3 (3)”“−3 (4)”“−4 (3)”“−5 (3)”“−5 (3)”
Average pruritus NRS score <4, n (%)“11 (29)”“17 (47)”“21 (58)”“27 (69)”“27 (69)”“28 (72)”
Worst pruritus NRS score <4, n (%)“10 (26)”“17 (47)”“18 (50)”“26 (67)”“27 (69)”“29 (74)”
Median change in average and worst pruritus NRS at week 12 by dose in the congress poster
Week 12 pruritus NRS change from baseline, median (IQR)Placebo, N = 38ESK-001 10 mg QD, N = 36ESK-001 20 mg QD, N = 36ESK-001 20 mg BID, N = 39ESK-001 40 mg QD, N = 39ESK-001 40 mg BID, N = 39
Average pruritus NRS“0.0 (-3.0, 1.0)”“-2.0 (-3.0, 0.0)”“-2.5 (-6.0, 0.0)”“-3.0 (-5.0, -2.0)”“-5.0 (-6.0, -3.0)”“-4.0 (-8.0, -3.0)”
Worst pruritus NRS“-0.5 (-2.0, 1.0)”“-2.0 (-4.0, -1.0)”“-2.5 (-5.0, 1.0)”“-4.0 (-6.0, -1.0)”“-5.0 (-7.0, -3.0)”“-5.0 (-7.0, -3.0)”
EQ-5D results

No evidence found.

Safety results
Treatment-emergent adverse events by dose in the safety analysis set
Outcome, n (%)Placebo, N = 38ESK-001 10 mg QD, N = 36ESK-001 20 mg QD, N = 36ESK-001 20 mg BID, N = 39ESK-001 40 mg QD, N = 39ESK-001 40 mg BID, N = 39ESK-001 pooled, N = 189
TEAEs“15 (39.5)”“19 (52.8)”“14 (38.9)”“18 (46.2)”“19 (48.7)”“25 (64.1)”“95 (50.3)”
TEAEs leading to treatment discontinuation“0 (0.0)”“0 (0.0)”“2 (5.6)”“0 (0.0)”“2 (5.1)”“1 (2.6)”“5 (2.6)”
TEAEs grade 3 or higher“0 (0.0)”“3 (8.3)”“1 (2.8)”“3 (7.7)”“3 (7.7)”“0 (0.0)”“10 (5.3)”
TEAEs related to study drug“5 (13.2)”“3 (8.3)”“3 (8.3)”“5 (12.8)”“7 (17.9)”“9 (23.1)”“27 (14.3)”
Headache“2 (5.3)”“0 (0.0)”“2 (5.6)”“3 (7.7)”“4 (10.3)”“3 (7.7)”“12 (6.3)”
Upper respiratory tract infection“0 (0.0)”“2 (5.6)”“2 (5.6)”“1 (2.6)”“2 (5.1)”“3 (7.7)”“10 (5.3)”
Nasopharyngitis“3 (7.9)”“2 (5.6)”“0 (0.0)”“1 (2.6)”“1 (2.6)”“3 (7.7)”“7 (3.7)”
SAEs“0 (0.0)”“1 (2.8)”“0 (0.0)”“3 (7.7)”“1 (2.6)”“0 (0.0)”“5 (2.6)”
Deaths“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”
Overall tolerability, common adverse events, and absence of tuberculosis, herpes zoster, opportunistic infections, and oral ulcers in the published article

“ESK-001 was generally safe and well-tolerated in adult patients with moderate-to-severe psoriasis following 12 weeks of treatment and 4 weeks off treatment, with no dose-limiting safety findings and a study drug discontinuation rate of 2.6% due to AEs” (opens the source at this quote in a new tab)

“There were no deaths in this study.” (opens the source at this quote in a new tab)

“Overall, the most common AEs (occurring in >5% of patients in any treatment group) were headache (6.3%), upper respiratory tract infections (5.3%), and nasopharyngitis (3.7%).” (opens the source at this quote in a new tab)

“Rates of acne and folliculitis were 2.1% and 1.6%, respectively, with no dose dependency (data on file).” (opens the source at this quote in a new tab)

“AEs were reported in 40% and in 39% to 64% of the patients in the placebo group and active-drug groups, respectively, with the highest percentage in the 40 mg BID dose group.” (opens the source at this quote in a new tab)

“TEAEs related to study drug occurred in 23% of subjects receiving 40 mg BID dose, 14.3% of subjects in pooled ESK-001 groups, and 13.2% of placebo subjects.” (opens the source at this quote in a new tab)

“Across all groups, the majority of TEAEs were mild or moderate and resolved.” (opens the source at this quote in a new tab)

“There were no cases of tuberculosis, herpes zoster, opportunistic infections, or oral ulcers.” (opens the source at this quote in a new tab)

“In addition, laboratory and electrocardiogram findings showed no meaningful changes during 12 weeks of ESK-001 treatment” (opens the source at this quote in a new tab)

Serious adverse events by arm, with the gastrointestinal event in the 20 mg twice-daily arm reported as enterocolitis, enteritis, or colitis and enteritis
Other adverse events reported in at least 5% of participants in any arm in the ClinicalTrials.gov results
Other (not serious) adverse event, affected / at risk (%)PlaceboESK-001 10 mg QDESK-001 20 mg QDESK-001 20 mg BIDESK-001 40 mg QDESK-001 40 mg BID
Total“9/38 (23.68%)”“8/36 (22.22%)”“4/36 (11.11%)”“18/39 (46.15%)”“11/39 (28.21%)”“18/39 (46.15%)”
Diarrhea“0/38 (0.00%)”“1/36 (2.78%)”“0/36 (0.00%)”“2/39 (5.13%)”“1/39 (2.56%)”“0/39 (0.00%)”
Dyspepsia“0/38 (0.00%)”“0/36 (0.00%)”“0/36 (0.00%)”“2/39 (5.13%)”“0/39 (0.00%)”“0/39 (0.00%)”
Nausea“1/38 (2.63%)”“0/36 (0.00%)”“0/36 (0.00%)”“2/39 (5.13%)”“0/39 (0.00%)”“0/39 (0.00%)”
Pyrexia“0/38 (0.00%)”“0/36 (0.00%)”“0/36 (0.00%)”“1/39 (2.56%)”“0/39 (0.00%)”“2/39 (5.13%)”
Upper respiratory tract infection“0/38 (0.00%)”“2/36 (5.56%)”“2/36 (5.56%)”“1/39 (2.56%)”“2/39 (5.13%)”“3/39 (7.69%)”
Nasopharyngitis“3/38 (7.89%)”“2/36 (5.56%)”“0/36 (0.00%)”“1/39 (2.56%)”“1/39 (2.56%)”“3/39 (7.69%)”
COVID-19“3/38 (7.89%)”“0/36 (0.00%)”“0/36 (0.00%)”“1/39 (2.56%)”“0/39 (0.00%)”“1/39 (2.56%)”
Diabetes mellitus“0/38 (0.00%)”“2/36 (5.56%)”“0/36 (0.00%)”“1/39 (2.56%)”“0/39 (0.00%)”“0/39 (0.00%)”
Headache“2/38 (5.26%)”“0/36 (0.00%)”“2/36 (5.56%)”“3/39 (7.69%)”“4/39 (10.26%)”“3/39 (7.69%)”
Dizziness“0/38 (0.00%)”“0/36 (0.00%)”“0/36 (0.00%)”“2/39 (5.13%)”“1/39 (2.56%)”“0/39 (0.00%)”
Cough“0/38 (0.00%)”“0/36 (0.00%)”“0/36 (0.00%)”“2/39 (5.13%)”“0/39 (0.00%)”“2/39 (5.13%)”
Acne“0/38 (0.00%)”“0/36 (0.00%)”“0/36 (0.00%)”“0/39 (0.00%)”“2/39 (5.13%)”“2/39 (5.13%)”
Dermatitis acneiform“0/38 (0.00%)”“1/36 (2.78%)”“0/36 (0.00%)”“0/39 (0.00%)”“0/39 (0.00%)”“2/39 (5.13%)”
Absence of MACE, serious infections, treatment-related thromboses, and laboratory or ECG trends in the congress presentation
Study limitations
Summary
  • The authors cite the small sample size per treatment group and the 16-week study duration, and the exclusion of participants who were previously nonresponders to IL-17, IL-12, or IL-23 targeted therapies. The protocol also excluded participants with lack of response to 2 or more biologic therapies.
  • The primary endpoint was assessed at week 12, when, according to the authors, response trajectories suggested maximal efficacy had not yet been achieved.
  • The statistical analysis plan states that no adjustments for multiplicity were performed.
  • The analysis population for efficacy differs by source: the protocol planned intent-to-treat analyses, the article used the modified intent-to-treat population, and the ClinicalTrials.gov results describe the PASI 75 population as all randomized and treated participants. The 20 mg BID arm has 40 participants in the intent-to-treat set and 39 in the modified intent-to-treat and safety sets.
  • The number of sites is 30 in the article, 53 in the ClinicalTrials.gov record, and approximately 65 planned in the protocol.
  • The serious gastrointestinal event in the 20 mg BID arm is reported as enterocolitis (article table footnote), enteritis of unknown etiology (article text), colitis and enteritis as separate terms (ClinicalTrials.gov results), and colitis and enteritis in one subject (congress presentation).
  • The article reports 5 participants (2.6%) discontinuing envudeucitinib due to an AE; the ClinicalTrials.gov participant flow lists an adverse event as the reason for not completing the study for 2 (20 mg QD), 1 (40 mg QD), and 1 (40 mg BID) participants.
  • The DLQI decrease of at least 4 points with 40 mg BID is 65% in the article and 62% in the patient-reported outcomes poster.
  • Acne and folliculitis rates are cited as data on file, skin biopsies were optional and collected from approximately 5 to 12 participants per dose group, and the report holds no EQ-5D results.